Sodium Phenylbutyrate

苯基丁酸钠

Report date: 2026/04/08 20:02:35
NMEFirst In Class

Base Information

Drug NameSodium Phenylbutyrate
Drug Alias Name苯丁酸钠Phenylbutyric acid sodium saltsodium phenylbutyrateLunaphenTriButyrate +[16] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone deacetylase inhibitors
TargetsHistone deacetylase
Therapy Area/IndicationsCombined D,L-2-hydroxyglutaric AciduriaSolid tumoursDiabetes Mellitus +[16] 
Global Approved IndicationsOrnithine Carbamoyltransferase Deficiency DiseaseCitrullinemiaCarbamoyl-Phosphate Synthase I Deficiency Disease +[4] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved DateN/A
Country/TerritoryUnited StatesEUMainland China +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesUcyclyd Pharma
China Registration ClassN/A

Develop Information

Active CompaniesZevra Therapeutics IncRelief Therapeutics Holding AGImmedica Pharma Ab +[6] 
Inactive CompaniesUtah State UniversityHorizon Therapeutics Usa IncAcer Therapeutics Inc +[7] 
Active IndicationsCombined D,L-2-hydroxyglutaric AciduriaDiabetes MellitusMultiple Acyl Coenzyme A Dehydrogenase Deficiency +[8] 
Inactive IndicationsSolid tumoursSpinal Muscular Atrophies of ChildhoodMuscular Atrophy, Spinal +[8] 

Other Information

ATC CodeA16AX03
Related LinksWikipediaDrugBankKEGG